百济神州：First full-year profitability driven by robust BTK sales-20260302

2 Mar 2026 CMB International Global Markets | Equity Research | Company Update BeOne Medicines (ONC US) BeOne Medicines (ONC US) - First full-year profitability driven by robust BTK sales BeOne's strong commercial momentum and ongoing cost discipline continue to translate into improving profitability, notwithstanding management's FY26 revenue guidance of US$6.2–6.4bn, which is modestly below our prior estimate of US$6.6bn. We continue to see substantial upside for Zanubrutinib (Zanu) to gain market share in ...